James Investment Research’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

James Investment Research’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-25,150	Closed	-$665K	–	842
2019 Q1	$665K	Sell	25,150 -29,750	-54%	-$705K	0.04%	380
2018 Q4	$1.07M	Buy	+54,900	New	+$1.08M	0.07%	299
2018 Q1	–	Sell	-131,490	Closed	-$1.92M	–	871
2017 Q4	$1.92M	Buy	+131,490	New	+$1.85M	0.07%	310

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

James Investment Research's HZNP Position: Q2 2019 in Review

James Investment Research sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2019, closing a stake of 25,150 shares — an estimated $665K sold.

James Investment Research first reported a position in HZNP in Q4 2017 and held it in 3 quarters. The position peaked at $1.92M in Q4 2017. 272 funds tracked by Wall St. Rank hold HZNP as of Q2 2019.

James Investment Research reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2019 after selling out during the quarter.
James Investment Research sold 25,150 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2019, an estimated $665K.
James Investment Research first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2017 and held it in 3 quarters.
James Investment Research's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.92M in Q4 2017.
272 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2019.

Based on James Investment Research's 13F filing for Q2 2019, filed 24 Jul 2019.